Vasodilators in patients with chronic obstructive pulmonary disease and pulmonary hypertension: not ready for prime time!


questions in a population that comprises only 4 to 5% of all NSCLC cases? I believe that we should design trials that address these issues in all age groups, with stratification based on age. I do not believe that trials restricted to elderly patients will meet accrual goals, and I believe that, with the data of Wisnivesky colleagues, these questions are… (More)
DOI: 10.1164/rccm.200911-1723ED


  • Presentations referencing similar topics